Study of a new drug for advanced ovarian cancer
Treatments studied
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This trial tests a new drug called IMNN-001 combined with standard chemotherapy for women with advanced ovarian, fallopian tube, or peritoneal cancer. The goal is to see if adding this drug can improve safety and effectiveness.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman aged 18 or older with a diagnosis of advanced high-grade ovarian, fallopian tube, or primary peritoneal cancer (stage IIIB/C or IV).
- Your tumor is of a non-mucinous type (like serous, endometrioid, or mixed).
- You are able to receive chemotherapy before surgery (neoadjuvant).
- You agree to provide a tumor sample for biomarker testing (HRD vs HRP).
- You have adequate organ function (bone marrow, kidney, liver) and a good performance status (ECOG 0-2).
- You are not pregnant, not breastfeeding, and willing to use effective birth control if applicable.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an immune-based treatment (IMNN-001/GEN-1) combined with standard chemotherapy given before and during surgery. It’s for people with newly diagnosed advanced high-grade serous ovarian, fallopian tube, or primary peritoneal cancer to see if it can improve outcomes.
This study tests a new drug (IMGN151) given intravenously, alone or with other therapies, for people with certain gynecologic cancers, specifically high-grade serous ovarian, fallopian tube, or primary peritoneal cancer. The goal is to see how well it works and what side effects might occur.
This trial tests an investigational drug called TORL-1-23 for people with ovarian cancer that has stopped responding to platinum chemotherapy. It aims to see if the drug can help shrink or control the cancer.
This trial tests combining surgery with an immunotherapy drug (sintilimab) for women whose ovarian cancer has returned after initial treatment. It aims to see if this approach can improve outcomes for people with specific tumor markers.
This trial tests a new drug called IBI354 against standard chemotherapy for people with ovarian, primary peritoneal, or fallopian tube cancer that stopped responding to platinum-based treatments. It aims to see if the new drug works better and has fewer side effects.
This trial tests a combination treatment for advanced ovarian cancer that hasn't been treated before. It combines chemotherapy, a personalized vaccine made from your own immune cells, and a drug called pembrolizumab to help your immune system fight the cancer.
Hear when a new Epithelial Ovarian Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.